Hikma Pharmaceuticals Share News (HIK)

LONDON MARKET MIDDAY: "Risky" Oil Price Rally Supports Stocks

WINNERS & LOSERS SUMMARY: Pathfinder Sinks After Mozambique Ruling

Hikma filing for generic of Glaxo's Advair Diskus accepted by US FDA

(ShareCast News) - Hikma Pharmaceuticals said on Friday that its abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder has been accepted for filing by the Food and Drug Administration in the US. The product is the generic version of GlaxoSmithKline's Advair Dis

LONDON MARKET OPEN: Resource Stocks Lead Gainers As Oil Recovers

US Accepts Hikma, Vectura Filing For Generic Of Glaxo's Advair Diskus

London-listed pharmas rally as Pfizer-Allergan deal collapses

(ShareCast News) - Shares in pharmaceuticals companies Shire, AstraZeneca and GlaxoSmithKline rallied on Wednesday as investors bet that the termination of Pfizer's agreement to buy Allergan might make the London-listed companies bid targets. US drug maker Pfizer said on Wednesday that its $160bn ag

Director dealings: Hikma boss buys £600K worth of shares

(ShareCast News) - The chairman and chief executive of Hikma Pharmaceuticals has purchased more than £600,000 worth of shares in the drugmaker. Said Darwazah bought 30,000 shares for 2,055.00p each, totalling £616,499.98 JP Morgan on Wednesday reiterated its 'overweight' rating on the stock and set

DIRECTOR DEALINGS: Hikma Chief Darwazah Builds Stake Through Darhold

Dividends Calendar - Week Ahead

Hikma subsidiary receives FDA approval for Temozolomide capsules

(ShareCast News) - Hikma Pharmaceuticals' fully-owned subsidiary West-Ward Pharmaceuticals has received approval from the US Food and Drug Administration for its abbreviated new drug application for Temozolomide capsules. Temozolomide is a chemotherapy agent used to treat a severe form of brain canc

DIRECTOR DEALINGS: Hikma Non-Executive Ups Interest

BROKER RATINGS SUMMARY: JPMorgan Starts Countryside At Overweight

DIRECTOR DEALINGS: Hikma Pharmaceuticals Director Buys 2,500 Shares

BROKER RATINGS SUMMARY: Goldman Sachs Starts Ascential With Buy Rating

LONDON MARKET CLOSE: UK Budget Lifts Stocks As Focus Turns To Fed